Skip to main content

Stocks

AI Stock Screener ALVIS Describe a screen in plain English — or filter by any metric across every US-listed stock. One free screen — no signup

Short interest & flow

Most Shorted Highest short interest
Squeeze Risk Composite short-squeeze score
Largest Short Volume Daily short-volume leaders
Highest Off-Exchange Share Dark-pool / OTC volume leaders

Ownership & fundamentals

Insider Sentiment Where insiders are accumulating most
Largest Buybacks Biggest share-repurchase programs
Going-Concern Flags Companies disclosing going-concern doubt

Institutions

Filers & Rankings

Browse Filers All 13F institutional filers
Top by AUM Largest filers by assets
Smart Money Index Top funds' highest-conviction basket
Superinvestors Famous value investors' portfolios
AUM Movers Biggest assets-under-management swings
Most-Held Stocks Stocks owned by the most filers
Last Quarter's Movers Notable position changes
Overlap Matrix Compare filer portfolios side by side
Clone Backtest Backtest a combined clone of several filers
Beneficial Ownership Recent 13D / 13G >5% stakes

13F Activity

13F Statistics Aggregate filing statistics
Latest Filings Newest 13F submissions
13F Trends Sector and flow trends
Double-Down Report Increased-conviction buys
Conviction Heat Map Crowded positions at a glance

Markets

Insider Trading Corporate insider buys and sells
Funds & ETFs Registered funds and ETFs from Form NPORT-P
Investment Advisers SEC-registered Form ADV firms
Economic Data Federal Reserve and macro indicators
Economic Calendar Upcoming macro data releases
FDA Calendar Upcoming FDA advisory-committee meetings
IPO Feed S-1 registrations turned into structured data
Congress Net Worth Richest members by disclosed net worth
Congress Leaderboard Members ranked by portfolio performance

Resources

Research Data-driven market research & single-stock theses
Blog Guides to filings & financials, plus tool comparisons
Announcements Product updates, new data & milestones

Docs Pricing ALVIS AI

Log in Start free

Navigation

Explore Equibles

Ask ALVIS AI analyst Research any US stock with every answer cited.

Explore the platform

Tap to expand

Stocks Screener, short data & fundamentals

AI Stock Screener Start here

Short interest & flow

Most Shorted Squeeze Risk Largest Short Volume Highest Off-Exchange Share

Ownership & fundamentals

Insider Sentiment Largest Buybacks Going-Concern Flags

Institutions 13F filings, portfolios & smart money

Filers & Rankings

Browse Filers Top by AUM Smart Money Index Superinvestors AUM Movers Most-Held Stocks Last Quarter's Movers Overlap Matrix Clone Backtest Beneficial Ownership

13F Activity

13F Statistics Latest Filings 13F Trends Double-Down Report Conviction Heat Map

Markets Insiders, funds, macro, IPOs & Congress

Insider Trading Funds & ETFs Investment Advisers Economic Data Economic Calendar FDA Calendar IPO Feed Congress Net Worth Congress Leaderboard

Resources Research, guides & product news

Research Blog Announcements

Docs Pricing Datasets

Start free Log in

No credit card · one-step email sign in

Home
Kevin

Kevin

Analyst

Analyst — Goldman Sachs

Earnings-call appearances

Amylyx Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Amylyx Pharmaceuticals, Inc. (AMLX)

2026-03-03

© 2026 Equibles

Stocks Research Blog Announcements Docs MCP API Datasets Data & API Pricing About Terms Privacy Contact

Congress Net Worth Congress Trades Economic Data High Yield Spread Core CPI Aaa Bond Yield Most Shorted Stocks Largest Buybacks

Please leave this field empty

Report a Problem

Category

Description

Email (optional, for follow-up)